Anticoagulation Therapy After Left Ventricular Assist Device Implantation

DOI DOI Web Site Web Site Web Site ほか2件をすべて表示 一部だけ表示 被引用文献1件 参考文献20件 オープンアクセス

書誌事項

タイトル別名
  • Survival of HeartMate II Patients Despite Cessation of Anticoagulation ― Outcomes and Hemostatic Analysis ―

この論文をさがす

説明

<p>Background:In long-term left ventricular assist device (LVAD) therapy, recurrent bleeding events may justify cessation of anticoagulation therapy (AT). However, data about THE safety and risks of AT cessation in LVAD patients are scarce.</p><p>Methods and Results:Between 2010 and 2015, 128 patients received a HeartMate II (HMII). Following recurrent bleeding events, we ceased vitamin K antagonist (VKA) therapy in 13 patients (10%) (no-VKA group). To characterize the hemostatic profile, we performed von Willebrand factor (vWF), platelet function (PF), and other hemostatic tests in all HMII patients. The incidence of pump thrombosis (PT), ischemic stroke (IS) and bleeding events in this HMII population was 4.7 %, 6.2% and 36.7%, respectively. Median survival without VKA was 435 days. No cases of PT and only 1 of IS occurred after AT discontinuation. All patients had impaired PF and acquired von Willebrand syndrome (AvWS). However, the vWF collagen-binding activity to antigen ratio before and after VKA cessation was significantly lower in the no-VKA group compared with the HMII population (0.60±0.12 vs. 0.73±0.14, P=0.006). The thrombin-antithrombin III complex (TAT) value was significantly higher in the no-VKA group (P=0.0005).</p><p>Conclusions:We experienced good results with AT cessation in specific HMII patients. The simultaneous onset of AvWS and high TAT values could explain at least in part the low thromboembolic rate in HMII patients without VKA.</p>

収録刊行物

  • Circulation Journal

    Circulation Journal 82 (5), 1309-1318, 2018

    一般社団法人 日本循環器学会

被引用文献 (1)*注記

もっと見る

参考文献 (20)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ